Anti-cavity drug in C3 Jian's phase 2 clinical trial targets elimination of streptococcus mutans
from Dentistry IQ
C3 Jian Inc., a private company focused on providing improved oral healthcare, recently announced that it has successfully completed the initial phase two clinical trial for its novel drug, C16G2. The company's drug targets the specific elimination of streptococcus mutans, the acid producing bacterium associated with dental caries or tooth decay.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063